Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea-Reference-Cited by-同舟云学术

Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea

Published:2022-01-10 Issue:1 Volume:10 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacology Res & Perspec

Author:

Yang Hyeri¹,Choi Eunmi¹^ORCID,Park Eunjun¹,Na Eonji¹,Chung Soo Youn¹,Kim Bonggi¹^ORCID,Han Soon Young¹

Affiliation:

1. Department of Drug Safety Information Korea Institute of Drug Safety and Risk Management Gyeonggi‐do Republic of Korea

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.910

Reference31 articles.

1. World Health Organization. Global report on diabetes.2020.

2. American Diabetes Association. Standards of medical care in diabetes.2019.

3. Overview of the efficacy and safety of SGLT‐2 inhibitors in Type 2 diabetes mellitus;Miller EM;J Fam Pract,2017

4. SGLT inhibitors in management of diabetes

5. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ‘Case of the Month’ from Herlev and Gentofte Hospital, Denmark: candidaemia and fungus ball in a patient with diabetes on sodium‐glucose co‐transporter 2 inhibitor;BJU International;2024-07-14

2. Genito Urinary Infection and Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Receiving SGLT2 Inhibitors: Evidence from a Systematic Literature Review of Landmark Randomized Clinical Trial;Drug Research;2024-07-11

3. Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far;Clinical Drug Investigation;2024-03-09

4. Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review;Current Diabetes Reports;2024-03-01

5. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems—A Literature Review;International Journal of Molecular Sciences;2024-02-06